Silvia Sedda

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Journal: American journal of therapeutics

Published: July 23, 2026

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Journal: American journal of therapeutics

Published: July 23, 2026

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.

Journal: Advances in therapy

Published: February 11, 2026

Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.

Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.

Journal: Journal of clinical medicine

Published: August 27, 2025

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study.

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study.

Journal: Intestinal research

Published: April 29, 2025

Filgotinib to Treat Acute Severe Refractory Ulcerative Colitis: A Case Report and Review of the Literature.

Filgotinib to Treat Acute Severe Refractory Ulcerative Colitis: A Case Report and Review of the Literature.

Journal: Case reports in gastroenterology

Published: December 10, 2024

Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.

Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.

Journal: Journal of clinical medicine

Published: September 23, 2024

Inflammatory cytokines: from discoveries to therapies in IBD.

Inflammatory cytokines: from discoveries to therapies in IBD.

Journal: Expert opinion on biological therapy

Published: August 03, 2019

mTOR sustains inflammatory response in celiac disease.

mTOR sustains inflammatory response in celiac disease.

Journal: Scientific reports

Published: August 01, 2019

Targeting IL-23 in Crohn's disease.

Targeting IL-23 in Crohn's disease.

Journal: Expert review of clinical immunology

Published: September 19, 2018

Oligonucleotide-Based Therapies for Inflammatory Bowel Disease.

Oligonucleotide-Based Therapies for Inflammatory Bowel Disease.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: June 28, 2018

Follistatin-like protein 1 sustains colon cancer cell growth and survival.

Follistatin-like protein 1 sustains colon cancer cell growth and survival.

Journal: Oncotarget

Published: June 05, 2018

Showing 1-12 of 31

Last Updated: 09/26/2026